Announced a rolling update of the medium- to long-term growth strategy and newly set financial forecasts for FY2031. Targets include net sales of 464 billion yen, operating income of 59.8 billion yen, operating margin of 12.9%, overseas sales ratio of 56%, and a payout ratio of 40%.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4527","jir_company_name":"Rohto Pharmaceutical Co.,Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4527-20261002-01.pdf","jir_short_summary":"Announced a rolling update of the medium- to long-term growth strategy and newly set financial forecasts for FY2031. Targets include net sales of 464 billion yen, operating income of 59.8 billion yen, operating margin of 12.9%, overseas sales ratio of 56%, and a payout ratio of 40%.","jir_summary":"### Update of Medium- to Long-Term Strategy\nThe Rohto Group operates the \"Medium- to Long-Term Growth Strategy 2025\u20132035\" on a rolling-update basis and has reorganized financial forecasts with FY2031 set as the new target year. The strategy centers on strengthening business earnings power, deepening technical and product capabilities, and expanding the medical business foundation, aiming to achieve sustainable growth and improved financial soundness through strategy execution.\n\n### FY2031 Financial Targets and Shareholder Returns\nThe FY2031 targets were announced as net sales of 464 hundred million yen, operating income of 59.8 hundred million yen, operating margin of 12.9%, overseas sales ratio of 56%, and payout ratio of 40%. The company revised the prior FY2030 forecasts and emphasizes maintaining financial soundness metrics such as ROE above 10% while balancing growth investments and shareholder returns.","jir_financial_highlights":"FY2031 Financial Target - Net Sales: 464 hundred million yen (Updated from previous forecast (rolling update))\nFY2031 Financial Target - Operating Income: 59.8 hundred million yen (Updated from previous forecast (rolling update))\nFY2031 Financial Target - Operating Margin: 12.9% (Updated from previous forecast (rolling update))\nOverseas Sales Ratio: 56% (Target after rolling update)\nPayout Ratio: 40% (Target after rolling update)","jir_category":"","jir_hashtags":"#RohtoPharmaceutical, #MediumToLongTermGrowthStrategy, #FinancialForecast, #RollingUpdate","jir_key_figures":"FY2031 Net Sales: 464 hundred million yen\nFY2031 Operating Income: 59.8 hundred million yen\nFY2031 Operating Margin: 12.9%\nOverseas Sales Ratio: 56%\nPayout Ratio: 40%","jir_meta_title":"Rohto Pharmaceutical Co.,Ltd. - Update to Medium- to Long-Term Growth Strategy 2026 and Announcement of FY2031 Financial Forecasts | October 2026","jir_meta_description":"Rohto Pharmaceutical implemented a rolling update of its Medium- to Long-Term Growth Strategy 2025\u20132035 and announced financial forecasts for FY2031 targeting net sales of 464 hundred million yen, operating income of 59.8 hundred million yen, and a payout ratio of 40%, with disclosure of overseas ratio and ROE targets.","jir_og_title":"Rohto Pharmaceutical - Announces Update to Medium- to Long-Term Strategy and FY2031 Forecasts","jir_og_description":"Rohto Pharmaceutical announced a rolling update to its medium- to long-term strategy and FY2031 financial forecasts, targeting net sales of 464 hundred million yen, operating income of 59.8 hundred million yen, a payout ratio of 40%, and an overseas sales ratio of 56%.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7770,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-127117","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n